The Technical Analyst
Select Language :
Cyclacel Pharmaceuticals [CYCCP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Cyclacel Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Cyclacel Pharmaceuticals is listed at the  Exchange

-4.06% $17.25

America/New_York / 27 mar 2024 @ 16:00


Cyclacel Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 2.40 mill
EPS: -2.05
P/E: -8.43
Earnings Date: N/A
SharesOutstanding: 0.139 mill
Avg Daily Volume: 0.0013 mill
RATING 2024-03-26
B-
Sell
RATINGS
Rating CashFlow: Neutral
Return On Equity: Strong Sell
Return On Asset: Strong Sell
DE: Sell
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/a
Gr.Profitn/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -8.43 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.43x
Company: PE -8.43 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 16.36 - 18.14

( +/- 5.17%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2023-12-21 Mcbarron Paul Buy 1 886 Common Stock
2023-12-21 Mcbarron Paul Buy 1 886 Warrants (right to buy)
2023-12-21 Rombotis Spiro George Buy 6 070 Common Stock
2023-12-21 Rombotis Spiro George Buy 6 070 Warrants (right to buy)
2023-06-30 Rombotis Spiro George Buy 110 000 Stock Option (right to buy)
INSIDER POWER
100.00
Last 94 transactions
Buy: 4 220 559 | Sell: 12

Forecast: 12:10 - $18.79

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
Volume Signals
Price $17.25 (-4.06% )
Volume 0.0000 mill
Avg. Vol. 0.0013 mill
% of Avg. Vol 0.311 %

Today

Intraday chart data with high, low, open and close for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

Last 12 Months

Last 12 months chart data with high, low, open and close for Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

RSI

Last 10 Buy & Sell Signals For CYCCP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock

CYCCP

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Last 10 Buy Signals

Date Signal @
QRVOMar 28 - 12:05$114.70
PLAYMar 28 - 12:0362.08
ZCUSXMar 28 - 11:54427.25
BONDUSDMar 28 - 12:025.04
SWTXMar 28 - 12:01$50.40
^BFXMar 28 - 11:47PTS3 835.39
BKRMar 28 - 12:01$33.39
MCHIMar 28 - 12:00$39.84
KCSUSDMar 28 - 11:59$12.45
HASMar 28 - 12:00$56.24

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.